Taiwan Liposome Company Completes US IPO

San Diego – January 3, 2019 – Cooley advised Taiwan Liposome Company on its $22.7 million initial public offering of 3,915,550 American Depository Shares – each representing two common shares. Partners Charlie Kim, Robert Phillips, James Lu and David Peinsipp led the Cooley team advising Taiwan Liposome Company.

Cantor acted as book-running manager for the offering. CLSA, HC Wainwright & Co., Janney Montgomery Scott and Laidlaw & Company UK Ltd. acted as book-runners.

Taiwan Liposome Company, whose securities now trade on the Nasdaq Global Market under the symbol “TLC,” is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology. 

Cooley has now represented the only two Taipei Exchange-listed companies to go public in the US to date – TLC and ASLAN Pharmaceuticals in June 2018. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.